Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 15/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6079614 | 0.86 | ALDH1A1 (0.48) | SIGMAR1OPRM1KCNH2ALDH1A1MEN1 | |
| SCHEMBL7257729 | 0.82 | TSHR (0.43) | SIGMAR1OPRM1KCNH2CYP2D6USP2 | |
| SCHEMBL6079472 | 0.79 | ALDH1A1 (0.45) | ALDH1A1KMT2A | |
| SCHEMBL6505799 | 0.78 | SIGMAR1 (0.40) | SIGMAR1OPRM1KCNH2DRD2CYP2D6 | |
| SCHEMBL6078497 | 0.76 | ALDH1A1 (0.41) | SIGMAR1OPRM1ALDH1A1 | |
| SCHEMBL6079709 | 0.75 | TRPV4 (0.38) | SIGMAR1OPRM1DRD2ALDH1A1 | |
| SCHEMBL6078572 | 0.74 | MGLL (0.43) | SIGMAR1OPRM1KCNH2DRD2CYP2D6 | |
| SCHEMBL7261674 | 0.73 | CYP3A4 (0.46) | CYP2D6ALDH1A1MEN1KMT2AUSP2 | |
| SCHEMBL7257549 | 0.73 | TSHR (0.43) | SIGMAR1OPRM1KCNH2CYP2D6ALDH1A1 | |
| SCHEMBL6078782 | 0.73 | SIGMAR1 (0.48) | SIGMAR1OPRM1KCNH2DRD2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122662-B2 | Tricyclic compound having spiro union | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2006-10-17 | — | — | US | disclosed |
| US-20050148769-A1 | Tricyclic compound having spiro union | MOCHIDA PHARMACEUTICAL CO., LTD. | 2005-07-07 | — | — | US | disclosed |
| US-6858599-B2 | Inhibitor for activated blood coagulation factor X | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2005-02-22 | — | — | US | disclosed |
| US-20040063716-A1 | Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1346994-A1 | CHOLESTEROL BIOSYNTHESIS INHIBITORS CONTAINING AS THE ACTIVE INGREDIENT TRICYCLIC SPIRO COMPOUNDS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
| US-20030045520-A1 | Tricyclic compound having spiro union | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063716-A1 | Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds | VKORC1, CYP46A1, TFPI | SIGMAR1 2556/4885OPRM1 4006/4885KCNH2 3064/4885 |
| US-20030045520-A1 | Tricyclic compound having spiro union | F2, TFPI, F11 | SIGMAR1 3298/4885OPRM1 3195/4885KCNH2 1817/4885 |
| US-20050148769-A1 | Tricyclic compound having spiro union | TFPI, F2, F12 | SIGMAR1 3914/4885OPRM1 3525/4885KCNH2 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.